The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

Trial Profile

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Veldoreotide (Primary) ; Octreotide
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Sponsors Aspireo Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 30 Apr 2014 New trial record
    • 03 Apr 2013 Results reported in an Aspireo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top